test

Rogerio C. Lilenbaum MD

Professor of Medicine (Medical Oncology); Chief Medical Officer of Smilow Cancer Hospital

Clinical Interests

lung cancer; lung cancer treatment in older patients


Board Certifications

1998
Hematology, Internal Medicine, Board Certified
1995
Internal Medicine, Board Certified
1997
Medical Oncology, Board Certified

Patient Care Locations

rogerio_lilenbaumfaculty-clinicsfalsetruetrue6truefalsefalse

Clinical Trials

ConditionsStudy Title
Lung Cancer, Anus, Bladder, Bones and Joints, Brain and Nervous System, Breast - Female, Breast - Male, Cervix Uteri, Colon, Corpus Uteri, Esophagus, Eye and Orbit, Hodgkin's Lymphoma, Ill-Defined Sites, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Multiple Myeloma, Non-Hodgkin's Lymphoma, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Male Genital, Other Urinary, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, and ThyroidA Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
LungA Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects With Advanced Non-Small Cell Lung Cancer
Bladder, Breast - Female, Lung, Pancreas, and StomachA Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors
Lung and Melanoma, skinA Phase 2 Study of MK-3475 in patients with metastatic melanoma and non-small cell lung cancer with untreated brain metastases
LungA Phase 2b, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects with Unresectable Pleural or Peritoneal Malignant Mesothelioma

More Clinical Trials...

Edit Profile